SCHEMBL4445381

SCHEMBL4445381

O=C(CCl)C1(c2ccccc2Cl)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 2/20 0.54
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
GRIN1 Q05586 4/20 0.39
GRIN2A Q12879 4/20 0.39
GRIN2D O15399 2/20 0.39
GRIN3B O60391 2/20 0.39
GRIN2B Q13224 2/20 0.39
GRIN2C Q14957 2/20 0.39
GRIN3A Q8TCU5 2/20 0.39
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
SLC6A4 P31645 2/20 0.36
OPRK1 P41145 1/20 0.36
LMNA P02545 1/20 0.36
OPRM1 P35372 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8747357 0.79 HDAC4 (0.59) HDAC4CRHBPCRHR2GRIN1GRIN2A
SCHEMBL30790659 0.79 HDAC4 (0.59) HDAC4CRHBPCRHR2GRIN1GRIN2A
SCHEMBL4284674 0.79 HDAC4 (0.59) HDAC4CRHBPCRHR2GRIN1GRIN2A
SCHEMBL29077524 0.78 HDAC4 (0.57) HDAC4CRHBPCRHR2GRIN1GRIN2A
SCHEMBL4440461 0.78 HDAC4 (0.47) HDAC4CRHBPCRHR2GRIN1GRIN2A
SCHEMBL4437243 0.77 HDAC4 (0.56) HDAC4HDAC3HDAC1HDAC2HDAC6
SCHEMBL5845612 0.76 HDAC4 (0.59) HDAC4LMNA
SCHEMBL3389625 0.76 HDAC4 (0.69) HDAC4CRHBPCRHR2GRIN1GRIN2A
SCHEMBL31729576 0.76 HDAC4 (0.69) HDAC4CRHBPCRHR2GRIN1GRIN2A
SCHEMBL4435171 0.76 AKR1C1 (0.52) HDAC4SLC6A4OPRK1LMNAOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2134692-A2 QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION Wyeth a Corporation of the State of Delaware (US) 2009-12-23 EP disclosed
US-20080255192-A1 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins WYETH (US) 2008-10-16 US disclosed
WO-2008121817-A2 QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION WYETH (US) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255192-A1 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins VCAM1, ICAM1, SELE HDAC4 2710/4885CRHBP 318/4885CRHR2 475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.